These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 1261795

  • 1. [Ifosfamide in comparison with cyclophosphamide in advanced ovarian carcinomas (author's transl)].
    Teufel G, Pfleiderer A.
    Geburtshilfe Frauenheilkd; 1976 Mar; 36(3):274-9. PubMed ID: 1261795
    [Abstract] [Full Text] [Related]

  • 2. Ifosfamide treatment of advanced ovarian cancer.
    Yazigi R, Wild R, Madrid J, Arraztoa J.
    Obstet Gynecol; 1984 Feb; 63(2):163-6. PubMed ID: 6694809
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of a cooperative clinical study of the cytostatic agent ifosfamide.
    Schnitker J, Brock N, Burkert H, Fichtner E.
    Arzneimittelforschung; 1976 Feb; 26(10):1783-92. PubMed ID: 798586
    [Abstract] [Full Text] [Related]

  • 4. Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast cancer.
    Buzdar AU, Legha SS, Tashima CK, Yap HY, Hortobagyi GN, Hersh EM, Blumenschein GR, Bodey GP.
    Cancer Treat Rep; 1979 Jan; 63(1):115-20. PubMed ID: 369682
    [Abstract] [Full Text] [Related]

  • 5. [Clinical experiences with holoxan within the framework of sequential combination therapy (author's transl)].
    Hartwich G, Neidhardt B, Lutz H.
    Med Klin; 1978 Sep 08; 73(36):1247-52. PubMed ID: 692477
    [Abstract] [Full Text] [Related]

  • 6. Chemotherapy of malignant ovarian tumors; therapeutic results of ifosfamide.
    Yakushiji M, Tsunawaki A, Nishida T, Nishimura H, Natsuaki Y, Inoue T, Kato T.
    Acta Obstet Gynaecol Jpn; 1981 Jul 08; 33(7):1071-6. PubMed ID: 7304132
    [Abstract] [Full Text] [Related]

  • 7. [Ifosfamide in the treatment of nephrotic syndrome (author's transl)].
    Gekle D, Daigeler C.
    Klin Padiatr; 1977 Sep 08; 189(5):370-5. PubMed ID: 562447
    [Abstract] [Full Text] [Related]

  • 8. [Combined chemotherapy of metastasing melanoblastoma using ifosfamide and cis-platinum (II)-diamminodichloride (author's transl)].
    Schmidt CG, Becher R.
    Dtsch Med Wochenschr; 1979 Jun 15; 104(24):872-5. PubMed ID: 446309
    [Abstract] [Full Text] [Related]

  • 9. [The problems of prophylactic chemotherapy, the second-look operation and the maintenance of the remission in the treatment of ovarian cancer (author's transl)].
    Pfleiderer A.
    Geburtshilfe Frauenheilkd; 1976 Feb 15; 36(2):132-9. PubMed ID: 1254157
    [Abstract] [Full Text] [Related]

  • 10. [Cytostatic treatment of hypernephroid renal carcinoma (author's transl)].
    König HJ, Hartwich G.
    Dtsch Med Wochenschr; 1980 Dec 26; 105(52):1810-4. PubMed ID: 7449648
    [Abstract] [Full Text] [Related]

  • 11. A phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy.
    Sørensen P, Pfeiffer P, Bertelsen K.
    Gynecol Oncol; 1995 Jan 26; 56(1):75-8. PubMed ID: 7821851
    [Abstract] [Full Text] [Related]

  • 12. Results obtained with fractionated ifosfamide massive-dose treatment in generalized malignant tumours.
    Brühl P, Günther U, Hoefer-Janker H, Hüls W, Scheef W, Vahlensieck W.
    Int J Clin Pharmacol Biopharm; 1976 Jul 26; 14(1):29-39. PubMed ID: 789266
    [Abstract] [Full Text] [Related]

  • 13. Ifosfamide plus cisplatin as primary chemotherapy of advanced ovarian cancer.
    Vallejos C, Solidoro A, Gómez H, Castellano C, Barriga O, Galdos R, Casanova L, Otero J, Rodriguez W.
    Gynecol Oncol; 1997 Nov 26; 67(2):168-71. PubMed ID: 9367702
    [Abstract] [Full Text] [Related]

  • 14. [Prevention of urinary tract toxicity of oxazaphosphorines by a "uroprotector". Report on a field study (author's transl)].
    Burkert H, Schnitker J, Fichtner E.
    MMW Munch Med Wochenschr; 1979 Jun 01; 121(22):760-2. PubMed ID: 112422
    [Abstract] [Full Text] [Related]

  • 15. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer.
    Gadducci A, Iacconi P, Cosio S, Fanucchi A, Cristofani R, Riccardo Genazzani A.
    Gynecol Oncol; 2000 Dec 01; 79(3):344-9. PubMed ID: 11104603
    [Abstract] [Full Text] [Related]

  • 16. [Clinical studies of ifosfamide for gynecological malignancies].
    Kohno I, Kazuta M, Miyao J, Kunimi N, Kawamoto M, Tanimura T, Fujiwara K, Sekiba K.
    Gan To Kagaku Ryoho; 1983 May 01; 10(5):1278-84. PubMed ID: 6870299
    [Abstract] [Full Text] [Related]

  • 17. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May 01; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 18. High-dose ifosfamide in advanced osteosarcoma.
    Marti C, Kroner T, Remagen W, Berchtold W, Cserhati M, Varini M.
    Cancer Treat Rep; 1985 Jan 01; 69(1):115-7. PubMed ID: 3855382
    [Abstract] [Full Text] [Related]

  • 19. [Treatment of bronchogenic cancer and lung metastases of solid tumors with ifosfamid (author's transl)].
    Hoefer H, Scheef W, Titscher R, Kokron O.
    Osterr Z Onkol; 1974 Jan 01; (1):3-7. PubMed ID: 4619650
    [No Abstract] [Full Text] [Related]

  • 20. Treatment of metastatic renal cancer with ifosfamide and mesnum with and without irradiation.
    Fosså SD, Talle K.
    Cancer Treat Rep; 1980 Jan 01; 64(10-11):1103-8. PubMed ID: 6780190
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.